Current concepts in the use of digitalis

Area of Science:

• Cardiology
• Pharmacology

Background:

• Digitalis glycosides have a long history in cardiac care, with clinical use often based on tradition.
• Understanding of cardiac pathophysiology and development of new agents necessitate a re-evaluation of digitalis' role.
• Digitalis toxicity management has improved with digoxin-specific Fab fragments.

Purpose of the Study:

• To revise the role of digitalis glycosides in managing supraventricular tachyarrhythmias and congestive heart failure.
• To highlight the emergence of alternative therapies and their impact on digitalis dependence.
• To differentiate treatment strategies based on cardiac dysfunction type (systolic vs. diastolic).

Main Methods:

• Review of current clinical practices and emerging therapeutic alternatives.
• Analysis of pathophysiology in congestive heart failure and arrhythmias.
• Comparison of efficacy and toxicity profiles of digitalis versus newer agents.

Main Results:

• Verapamil largely replaces digoxin for paroxysmal reentrant supraventricular tachyarrhythmias.
• Beta-blockers, verapamil, and diltiazem are effective for rate control in atrial fibrillation/flutter.
• Diastolic dysfunction in heart failure requires addressing underlying causes, not solely inotropic support.

Conclusions:

• Digitalis glycoside therapy requires careful patient selection and is no longer the sole primary approach.
• Alternative agents and therapies have reduced reliance on digitalis for arrhythmias and heart failure.
• Treatment for heart failure should be tailored to systolic or diastolic dysfunction, prioritizing underlying cause correction.